(9R)-9-chloro-11-17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10-13-16-trimethyl-6-7-8-11-12-14-15-16-octahydrocyclopenta[a]phenanthren-3-one and Hypereosinophilic-Syndrome

(9R)-9-chloro-11-17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10-13-16-trimethyl-6-7-8-11-12-14-15-16-octahydrocyclopenta[a]phenanthren-3-one has been researched along with Hypereosinophilic-Syndrome* in 1 studies

Reviews

1 review(s) available for (9R)-9-chloro-11-17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10-13-16-trimethyl-6-7-8-11-12-14-15-16-octahydrocyclopenta[a]phenanthren-3-one and Hypereosinophilic-Syndrome

ArticleYear
[Biotherapies for the treatment of asthma: are they the treatment of the future?].
    Revue des maladies respiratoires, 2006, Volume: 23, Issue:4 Pt 2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Asthma; Beclomethasone; Biological Therapy; Child; Controlled Clinical Trials as Topic; Disease Models, Animal; Eosinophilia; Etanercept; Forecasting; Glucocorticoids; Haplorhini; Humans; Hypereosinophilic Syndrome; Immunoglobulin E; Immunoglobulin G; Immunosuppressive Agents; Interleukin-5; Omalizumab; Receptors, Tumor Necrosis Factor; Time Factors; Tumor Necrosis Factor-alpha

2006